An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

BioMed Realty, a Blackstone portfolio company and the largest private operator of life science real estate, alongside Suffolk ...

The Public Theater and Ma-Yi Theater Company will soon present the New York premiere of SUMO, a thrilling new play written by ...

Investing.com -- Keros Therapeutics, Inc. (NASDAQ: KROS) shares rose 6% following the announcement of the effectiveness of its global license agreement with pharmaceutical giant Takeda. The deal, ...

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

DelveInsight's“Lennox–Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lennox–Gastaut syndrome, historical and forecasted ...

Tempus AI claims to have a one-stop-shop, with a flywheel platform that becomes better with each new client. See why I rate ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Masakazu Takeda draws on two other listed supporting ... Although the overall rating does not hinge on one-year performance figures, it is notable that this share class returned 28.0%, an ...

Perhaps the most surprising company on the rise is Takeda. The Japanese company rose ... comparison to previous years' performance pushed them down the table. Similar problems hit Novartis and ...